Effects of olmesartan medoxomil, an angiotensin II type 1 receptor antagonist, on plasma concentration of B-type natriuretic peptide, in hypertensive patients with type 2 diabetes mellitus: a preliminary, observational, open-label study

What Was Tested

Researchers studied BNP (Nesiritide) in this clinical trial publication.

Angiotensin II type 1 (AT1) receptor antagonists (angiotensin receptor blockers [ARBs]) are widely used for the treatment of not only hypertension but also cardiac dysfunction.

B-type natriuretic peptide (BNP) is secreted mainly by the cardiac ventricle and plays an important role in the regulation of blood pressure (BP) and body fluid.

The objective of this study was to determine the effects of olmesartan medoxomil, a novel ARB, on the plasma level of BNP in hypertensive patients with type 2 diabetes.

Who Took Part

The study group was 2 patients.

PubMed indexes the participants as middle-aged adults and older adults, both men and women.

Another group consisting of 22 age- and body mass index-matched subjects not treated with olmesartan medoxomil was observed for reference purposes.

How the Study Was Run

The researchers set it up as an open-label study.

Nothing was hidden in this open-label BNP (Nesiritide) study: the patients and staff both knew the treatment.

This was a preliminary, prospective, observational, open-label study.

What Was Measured

PubMed files the paper under topics including Angiotensin II Type 1 Receptor Blockers, Blood Pressure, Diabetes Mellitus, Type 2, Hypertension, Imidazoles, Natriuretic Peptide, Brain and Olmesartan Medoxomil.

What This Means in Plain Language

The paper is an open-label study of BNP (Nesiritide) in 2 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2011 (Clinical drug investigation), a journal based in New Zealand.

More context: the BNP (Nesiritide) compound page, all human trials.